​

Adaptimmune Therapeutics (ADAP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ADAP Stock Forecast

Adaptimmune Therapeutics (ADAP) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $2.83, with a high of $4.00 and a low of $1.00. This represents a 1079.17% increase from the last price of $0.24.

High: $4 Avg: $2.83 Low: $1 Last Closed Price: $0.24

ADAP Stock Rating

Adaptimmune Therapeutics stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (83.33%), 1 Hold (8.33%), 1 Sell (8.33%), and 0 Strong Sell (0.00%).

Buy
Total 12 0 1 1 10 Strong Sell Sell Hold Buy Strong Buy

ADAP Price Target Upside V Benchmarks

TypeNameUpside
StockAdaptimmune Therapeutics1079.17%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$2.79
Last Closing Price$0.24$0.24$0.24
Upside/Downside--1062.50%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25222-17
Mar, 25242-19
Feb, 25242-19
Jan, 25242-19
Dec, 24242-19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 30, 2024Arthur HeH.C. Wainwright$4.00$1.37191.97%1566.67%
May 30, 2024George FarmerScotiabank$3.15$1.01211.88%1212.50%
May 17, 2024Graig SuvannavejhMizuho Securities$3.00$1.20150.00%1150.00%
May 16, 2024Peter LawsonBarclays$1.00$1.20-16.67%316.67%
Nov 14, 2022Wells Fargo$3.00$2.5119.52%1150.00%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 21, 2025ScotiabankOutperformOutperformhold
Aug 05, 2024ScotiabankSector OutperformSector Outperformhold
Jul 30, 2024H.C. WainwrightBuyinitialise
May 31, 2024Wells FargoEqual-WeightEqual-Weighthold
May 30, 2024ScotiabankOutperforminitialise
May 16, 2024BarclaysUnderweightUnderweighthold
Jan 03, 2023GuggenheimBuyupgrade
Nov 09, 2022Bank of America SecuritiesBuyupgrade
Nov 09, 2022Mizuho SecuritiesBuyupgrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.15$-0.17$-0.17$-0.09$-0.05----
Avg Forecast$-0.89$-0.03$-1.09$-0.44$-0.03$-0.08$-0.50$-0.35$-0.08
High Forecast$-0.72$-0.03$-0.88$-0.40$-0.01$-0.06$-0.12$-0.04$-0.04
Low Forecast$-1.26$-0.05$-1.32$-0.49$-0.04$-0.10$-0.87$-0.66$-0.11
Surprise %-83.15%466.67%-84.40%-79.55%66.67%----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.96M$6.15M$27.15M$60.28M$178.03M----
Avg Forecast$4.14M$9.20M$27.41M$86.03M$182.53M$39.78M$69.45M$142.48M$236.06M
High Forecast$5.45M$12.11M$31.87M$108.41M$195.64M$45.50M$72.43M$142.73M$297.47M
Low Forecast$3.53M$7.85M$23.29M$55.03M$168.46M$33.30M$66.46M$142.23M$150.99M
Surprise %-4.33%-33.16%-0.95%-29.93%-2.47%----

Net Income Forecast

$-2B $-1B $-900M $-600M $-300M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-130.09M$-158.09M$-165.46M$-113.87M$-70.81M----
Avg Forecast$-129.73M$-6.43M$-176.17M$-113.87M$-44.52M$-97.00M$-600.05M$-93.23M$-101.78M
High Forecast$-103.78M$-5.20M$-140.93M$-91.10M$-8.98M$-78.02M$-147.38M$-45.34M$-54.10M
Low Forecast$-155.68M$-9.07M$-211.40M$-136.65M$-44.90M$-115.98M$-1.05B$-793.45M$-136.20M
Surprise %0.28%2359.27%-6.08%-59.08%----

ADAP Forecast FAQ

Is Adaptimmune Therapeutics stock a buy?

Adaptimmune Therapeutics stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Adaptimmune Therapeutics is a favorable investment for most analysts.

What is Adaptimmune Therapeutics's price target?

Adaptimmune Therapeutics's price target, set by 12 Wall Street analysts, averages $2.83 over the next 12 months. The price target range spans from $1 at the low end to $4 at the high end, suggesting a potential 1079.17% change from the previous closing price of $0.24.

How does Adaptimmune Therapeutics stock forecast compare to its benchmarks?

Adaptimmune Therapeutics's stock forecast shows a 1079.17% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Adaptimmune Therapeutics over the past three months?

  • April 2025: 28.57% Strong Buy, 28.57% Buy, 28.57% Hold, 0% Sell, 14.29% Strong Sell.
  • March 2025: 22.22% Strong Buy, 44.44% Buy, 22.22% Hold, 0% Sell, 11.11% Strong Sell.
  • February 2025: 22.22% Strong Buy, 44.44% Buy, 22.22% Hold, 0% Sell, 11.11% Strong Sell.

What is Adaptimmune Therapeutics’s EPS forecast?

Adaptimmune Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.08, marking a 60.00% increase from the reported $-0.05 in 2024. Estimates for the following years are $-0.5 in 2026, $-0.35 in 2027, and $-0.08 in 2028.

What is Adaptimmune Therapeutics’s revenue forecast?

Adaptimmune Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $39.78M, reflecting a -77.65% decrease from the reported $178.03M in 2024. The forecast for 2026 is $69.45M, followed by $142.48M for 2027, and $236.06M for 2028.

What is Adaptimmune Therapeutics’s net income forecast?

Adaptimmune Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-97.003M, representing an 36.98% increase from the reported $-70.814M in 2024. Projections indicate $-600M in 2026, $-93.229M in 2027, and $-102M in 2028.